A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

NCT05776888 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

NCT05147220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED

Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

NCT05566756 ·Status: COMPLETED

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

NCT02792218 ·Status: COMPLETED ·Phase: PHASE3

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779 ·Status: COMPLETED

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 ·Status: RECRUITING ·Phase: PHASE3

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

NCT04940065 ·Status: COMPLETED

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

NCT03593590 ·Status: COMPLETED

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231 ·Status: COMPLETED ·Phase: PHASE3

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716 ·Status: COMPLETED ·Phase: PHASE3

A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis

NCT05334472 ·Status: COMPLETED

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT05811416 ·Status: ACTIVE_NOT_RECRUITING

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

NCT06737419 ·Status: COMPLETED

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

NCT05199571 ·Status: COMPLETED ·Phase: PHASE4

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT05658601 ·Status: COMPLETED

Characterizing the Use of Ofatumumab in a Real World Setting

NCT05090033 ·Status: COMPLETED

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness of Ofatumumab in Real-world Practice

NCT06760624 ·Status: COMPLETED

Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition

NCT02598167 ·Status: COMPLETED

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555 ·Status: COMPLETED

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504 ·Status: RECRUITING ·Phase: PHASE3

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 ·Status: COMPLETED